When the next deadly pandemic flu hits, the first challenge will be to develop a vaccine. But looming behind that obstacle is another: How to get an inoculation to millions of people without inadvertently exacerbating the crisis.
On the 100th anniversary of the influenza pandemic of 1918 that sickened a third of the world's population and killed 50 million people, vaccine researchers are urgently searching for new approaches to prepare for the next pandemic — a threat that most public health officials consider inevitable. A new study provides proof of concept for a solution that could upend the traditional centralized model, in which health professionals give injections at clinics.
Researchers created an H5N1 vaccine, boosted by a special ingredient that primes the body's immune system to respond. Then, they administered it through a microneedle that only penetrates the upper layer of the skin. They see this prototype technology as a platform that could lead to novel vaccine patches that can be distributed rapidly and administered without a nurse. People would simply have to stick a bandage-like strip, lined with microscopic needles, onto their skin.
"It's an excellent, extremely comprehensive and well-done study,” said Mark Poznansky, director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, who was not involved in the research, which was published in Science Advances. “What they're suggesting is something you could stick in an envelope and get to people rapidly — it's an important breakthrough technology."
The research team combined several different technologies into their prototype: tiny, hollow microneedles that penetrate only the upper layer of the skin were paired with vaccines made from noninfectious “virus-like particles” that can be rapidly produced by tobacco plants. Crucially, researchers added another ingredient, called an adjuvant, that speeds up and strengthens the body's response to the vaccine.
The study, funded by the Defense Advanced Research Projects Agency, is still at an early stage. Large-scale human trials will be needed to determine the safety of the approach, which successfully protected ferrets from H5N1 and appeared safe in a small human trial to study safety.
Darrick Carter, a biochemist at the Infectious Disease Research Institute in Seattle, said that one of the most exciting things their study showed was that the adjuvant seemed to confer protection not just against the target virus but also to related viruses.
If that observation is borne out in further studies, it could address an important problem in vaccine development. If the strain of virus used to create the vaccine mismatches the pathogen that is out there circulating in the world, the vaccine becomes much less effective. The 2016-2017 flu vaccine was only moderately effective, for example, because of a mutation in the virus.
Because public health officials seeking to prepare for a pandemic flu won't know the exact strain in advance and the virus could change during an outbreak, vaccines that could be made more broadly effective with an adjuvant are exciting to researchers.
"If you think about the mechanics of how the stockpile is done, with a single virus and millions of doses — the probability of that exact virus emerging is, in my mind, fairly low,” Carter said.
Carter and colleagues are eager to move the work forward but say they have reached something of an impasse. While they were able to secure early funding to demonstrate the science behind the technique and show early proof of its clinical promise, they don't yet have a partner to try to scale up the effort and test it in a larger population.
As they search for support to move the research to the next step, they said they plan to apply the technology to an area of medicine where funding is typically more accessible: cancer. They hope that the adjuvant that stimulates the immune system could, if injected into a tumor, awaken the body's immune cells to attack the tumor.